Clinical worsening following discontinuation of tocilizumab in diffuse cutaneous systemic sclerosis: a single-centre experience in Japan.
Sign Up to like & getrecommendations! Published in 2022 at "Rheumatology"
DOI: 10.1093/rheumatology/keac136
Abstract: OBJECTIVE To investigate outcomes following the tapering or discontinuation of tocilizumab in patients with diffuse cutaneous systemic sclerosis (dcSSc) in a real-world setting. METHODS Fifteen patients who were treated with tocilizumab for dcSSc were selected… read more here.
Keywords: systemic sclerosis; discontinuation tocilizumab; tocilizumab; diffuse cutaneous ... See more keywords